Poewe W H, Lees A J, Stern G M
Department of Neurology, Middlesex Hospital, London, UK.
Eur Neurol. 1987;27 Suppl 1:93-7.
The efficacy of a novel oral sustained-release preparation of L-dopa (Madopar HBS) was compared to that of previous standard L-dopa treatment in 10 patients with idiopathic Parkinson's disease and severe fluctuations in motor performance in an open inpatient trial. Clinical assessment included evaluation of self-scoring 'on-off' diaries kept by the patients throughout the study. It revealed a reduction of end-of-dose deterioration and, to a lesser degree, of random 'on-off' swings in 6 cases. Doses of Madopar HBS required for an optimal response averaged the 1.6-fold of previous conventional L-dopa. Plasma levels of L-dopa were more stable with Madopar HBS compared to standard L-dopa treatment in 4 of 5 patients.
在一项开放性住院试验中，对10例特发性帕金森病且运动功能严重波动的患者，比较了新型左旋多巴口服缓释制剂（美多芭HBS）与既往标准左旋多巴治疗的疗效。临床评估包括对患者在整个研究过程中所记录的自我评分“开-关”日记进行评估。结果显示，6例患者的剂末恶化有所减轻，随机“开-关”波动也有一定程度减轻。获得最佳反应所需的美多芭HBS剂量平均为既往常规左旋多巴剂量的1.6倍。与标准左旋多巴治疗相比，5例患者中有4例使用美多芭HBS时左旋多巴的血浆水平更稳定。
